Clinical trials: Hyperparathyroidism; Secondary, Renal
Secondary Hyperparathyroidism, End Stage Renal Disease
Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism
Secondary hyperparathyroidism (sHPT) is common in patients with chronic kidney disease (CKD), including those who are undergoing long-term haemodialysis treatment.
- Conditions
- Secondary Hyperparathyroidism, End Stage Renal Disease, Parathyroid Hyperplasia
- Trial name
- NCT01421407
- Testing
- Ultrasonic ablation device
- Where
- 3 sites in Italy, Spain
- Sponsor
- Theraclion
Chronic Kidney Disease, Secondary Hyperparathyroidism
20070360 Incident Dialysis
Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis
- Trial name
- NCT00803712
- Testing
- Cinacalcet, Vitamin D
- Volunteers
- 313 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism
A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
The study is being conducted to evaluate the efficacy, and safety of Paricalcitol for secondary hyperparathyroidism with stage 3 and stage 4 chronic kidney disease in adults.
- Trial name
- NCT04994080
- Testing
- Paricalcitol
- Volunteers
- 84 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Chronic Kidney Disease, Secondary Hyperparathyroidism
Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease
Active forms of vitamin D and its analogs are used to treat elevated parathyroid hormone levels and bone disease in chronic kidney disease (CKD).
- Trial name
- NCT01426724
- Testing
- Contrast Enhanced Ultrasonography
- Where
- United States
- Sponsor
- University of Virginia
End-Stage Kidney Disease (ESKD), Cardiovascular Disease
Cardiovascular Mortality Prediction in Maintenance Hemodialysis Patients
This prospective, single-center observational cohort study evaluates cardiovascular mortality risk in adults receiving maintenance hemodialysis.
- Conditions
- End-Stage Kidney Disease (ESKD), Cardiovascular Disease, Secondary Hyperparathyroidism (SHPT)
- Trial name
- NCT07769190
- Testing
- One-Year Serum Phosphate Target Achievement Rate, Parathyroidectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Huashan Hospital
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Chronic Kidney Disease, Secondary Hyperparathyroidism
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
This study will compare CTAP201 with Doxercalciferol in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis, at different dose strengths.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Trial name
- NCT00792857
- Testing
- CTAP201 Injection, Doxercalciferol
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- OPKO IP Holdings II, Inc.
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Endstage Renal Disease
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.
- Trial name
- NCT02977117
- Testing
- Dialysate magnesium (1.0 mmol/L), Dialysate magnesium (0.5 mmol/L)
- Where
- Denmark
- Volunteers
- 59 people
- Sponsor
- Iain Bressendorff
CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Secondary Hyperparathyroidism
The Longitudinal PTH-Study
The main study aim is to quantify the agreement between the analytical results provided by two third generation and two second generation Parathyroid hormone (PTH) assays.
- Conditions
- CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Secondary Hyperparathyroidism, Kidney Replacement
- Trial name
- NCT03464149
- Testing
- One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)
- Where
- Austria
- Volunteers
- 132 people
- Sponsor
- Medical University of Vienna
Secondary Hyperparathyroidism
A Trial of SHR6508 in Secondary Hyperparathyroidism
The study is being conducted to evaluate the tolerability, pharmacokinetics and pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis
- Trial name
- NCT05221008
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Secondary Hyperparathyroidism
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous
The purpose of this study is to assess health-related Quality of Life (QoL) changes in participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT) undergoing hemodialysis and receiving paricalcitol…
- Trial name
- QUALITIZE (NCT01368042)
- Where
- 11 sites in Greece
- Volunteers
- 265 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease Mineral and Bone Disorder
The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density
The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and death.
- Trial name
- REPAIR-CKD (NCT07171216)
- Testing
- Treat to target
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Herlev Hospital
End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis
Activated Charcoal Use in Chronic Kidney Disease Patients
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification.
- Conditions
- End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT06906874
- Testing
- Activated Charcoal, Phosphate Binders
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Mansoura University
Chronic Kidney Disease, Hyperparathyroidism
Pediatric Chronic Kidney Disease Safety and Efficacy
The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease
- Trial name
- NCT01277510
- Testing
- cinacalcet capsule, Standard of Care
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 43 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, End Stage Kidney Disease
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-2 (NCT05836220)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 412 people
- Sponsor
- Pathalys Pharma
Hemodyalysis, Kidney Tansplant
Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general…
- Conditions
- Hemodyalysis, Kidney Tansplant, Osteoporosis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT07141043
- Where
- Romania
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Trial name
- IMPACT SHPT (NCT00977080)
- Testing
- Paricalcitol, Cinacalcet
- Where
- 83 sites in United States, Czechia and 10 more
- Volunteers
- 272 people
- Sponsor
- Abbott
Secondary Hyperparathyroidism, Diabetic Nephropathies
Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy
The aim of this study is to evaluate the prevalence of secondary hyperparathyroidism among patients with diabetic nephropathy.
- Trial name
- NCT03137316
- Testing
- intact parathyroid hormone level
- Volunteers
- 437 people
- Sponsor
- Benha University
Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism
Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia…
- Trial name
- Cin-ca (NCT07007338)
- Testing
- Supplementary blood samples and urines samples
- Where
- 7 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon